Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of
Amivantamab as a monotherapy and in combination with lazertinib, and to determine the
recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD)
(combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination
chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in
21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).